DIA EuroMeeting explores the road ahead for drug development in the EU and UK

Drug Information Association29 - 31 March 2017, Glasgow, United Kingdom.
DIA, (founded as the Drug Information Association) announced critical workshops to be held at the 2017 DIA EuroMeeting. The goal of the annual DIA EuroMeeting has always been to stimulate solutions by bringing together diverse stakeholder perspectives on issues affecting drug development in Europe.

Of particular importance for 2017, is the future impact of the Brexit decision across the European regulatory environment. With the European Medicines Agency (EMA) and over 1,200 QPPVs currently operating within the UK, practical solutions are needed for those roles that must legally reside in the EU. Critical stakeholders will share their perspectives on the path forward.

DIA EuroMeeting aims to bring together key healthcare stakeholder groups, such as industry, regulators, pharmacovigilance, and patients to discuss and share insights on practical solutions as well as longer term impacts of regulatory changes that need to be considered for both EU and UK citizens.

Key stakeholder group leaders include:

  • Virginia Acha, Executive Director Research, Medical and Innovation, ABPI, UK
  • Karl Broich, President, Federal Institute for Drugs and Medical Devices (BfArM), Germany
  • Elizabeth Kuiper, Director of European Affairs, EFPIA, Belgium
  • Jonathan Mogford, Director of Policy, MHRA, UK
  • Alan Morrison, Vice President Regulatory Affairs International, MSD, UK
  • Guido Rasi, Executive Director, European Medicines Agency (EMA), EU
  • Saad Shakir, Director, Drug Safety Research Unit (DSRU), UK

The 2017 EuroMeeting theme "Translational Health Care: From Bench to Bedside - and Back" also demonstrates the importance of incorporating learnings from actual patients into R&D. A new "DIAmond Session" introduces the critical theme of facilitating early patient access to innovative medicines, while the patient voice is directly incorporated in over a dozen sessions.

"Leaders across the pharmaceutical industry and regulatory agencies recognize the often conflicting goals of cost containment and accelerated access to new treatments," said Holger Adelmann, MD, PhD, Senior Vice President & Managing Director, DIA EMEA. "The path forward is achieved by multi-stakeholder collaboration, and DIA's EuroMeeting continues to be a destination for sparking these necessary conversations."

For further information, please visit:
http://www.diaglobal.org/en/flagship/euromeeting

About DIA
DIA (founded as the Drug Information Association) provides is a global, neutral forum where stakeholders can openly and freely exchange knowledge information and insights beyond boundaries to advance innovation in health care product development and lifecycle management globally. DIA is an international, nonprofit, multidisciplinary member association that provides health care product development professionals a neutral and transparent forum for collaboration and the exchange of insights to improve health globally through the advancement of lifesaving medicines and technologies. DIA builds knowledge through, learning solutions (digital and in person training), conferences and insights in the areas of, Regulatory Science, Translational Medicine, Patient Engagement and Value and Access for professionals in the pharmaceutical, biotechnology, and medical device communities.

Most Popular Now

Novartis drug Zykadia receives FDA Priority Review…

Novartis today announced that the US Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for filing, and granted Priority R...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Drugs similar to aspirin, ibuprofen could help tre…

A potentially life-saving treatment for sepsis has been under our noses for decades in the non-steroidal anti-inflammatory drugs (NSAIDs) most people have in their medici...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

Another record year for Bayer - good progress with…

Bayer had a very successful year in 2016, both strategically and operationally. Sales of the Bayer Group increased in 2016 by 1.5 percent (Fx & portfolio adj. 3.5 percent...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]